MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-812

  1. 5,071 Posts.
    lightbulb Created with Sketch. 567
    wow that sound like a convoluted way of doing things- would this not take time to get this done? isn't there a risk of novartis that soemthing else will comes along in the way of a competing treatment- while they are supposed to back stabbing...
    do we really know who petition the FDA for non approval?? your saying Novartis but if not them who would be advantaged? conspirary of a FDA knowing another companies treatment we be along soon

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.